Pfizer
Dr. Jeff Settleman is the Senior Vice President, Chief Scientific Officer for Oncology Research and Development and serves as the La Jolla site head. Dr. Settleman leads all oncology research from the beginning stages of discovery to proof of concept clinical studies.
Dr. Settleman is an internationally recognized leader in molecularly targeted cancer therapeutics, the epigenetics of cancer drug resistance, and personalized cancer medicine.
Dr. Settleman held numerous notable positions in both academic research and drug discovery before joining the Pfizer team. Prior to his current role, Dr. Settleman served as Distinguished Principal Investigator and Head of Oncology Research at Calico Life Sciences. Prior to Calico, Dr. Settleman led Discovery Oncology at Genentech.
Dr. Settleman served as a Professor at the Harvard School of Medicine for 18 years and during his tenure he was named the Laurel Schwartz Professor of Oncology. During that same timeframe, Dr. Settleman served as Director of the Center for Molecular Therapeutics and Scientific Director of the Massachusetts General Hospital Cancer Center and led the Cancer Cell Biology program of the Dana-Farber/Harvard Cancer Center.
Dr. Settleman’s impressive career began at the Whitehead Institute for Biomedical Research at MIT where he was a postdoctoral fellow in Oncology and Cancer Biology.
Dr. Settleman received his Ph.D. in Genetics from Yale University and his B.A. in Neuroscience from the University of Pennsylvania. He is the author of over 240 peer-reviewed publications, many of which have appeared in Cell, Science, and Nature.
This person is not in any offices
Pfizer
606 followers
Pfizer Inc. is a research-based, global biopharmaceutical company. They apply science and their global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. They work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Pfizer collaborates with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. Pfizer was founded in 1942. Most of Pfizer’s revenues come from the manufacture and sale of biopharmaceutical products. They believe that their medicines and vaccines provide significant value for healthcare providers and patients, through improved treatment of diseases, improvements in health, wellness and productivity as well as by reducing other healthcare costs, such as emergency room or hospitalization. Pfizer is committed to fulfilling their purpose: Breakthroughs that change patients’ lives. Their purpose fuels everything they do and reflects both their passion for science and commitment to patients. Pfizer’s growth strategy is driven by five “Bold Moves” that help them deliver breakthroughs for patients and create value for shareholders and other stakeholders: 1. Unleash the power of our people; 2. Deliver first-in-class science; 3. Transform our go-to-market model; 4. Win the digital race in pharma; and 5. Lead the conversation.